Wide Ranks

ACIU

AC Immune SA

3.36

Top Statistics
Market Cap 332 M Forward PE -110.78 Revenue Growth 0.00 %
Current Ratio 1.86 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -97.29 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.05 Enterprise / Revenue 4.41 Price To Sales Trailing12 Months 8.11
Profitability
Profit Margins -97.29 % Operating Margins 28.52 %
Balance Sheet
Total Cash 157 M Total Cash Per Share 1.58 Total Debt 3 M
Total Debt To Equity 2.37 Current Ratio 1.86 Book Value Per Share 1.30
All Measures
Short Ratio 810.00 % Message Board Id finmb_22309440 Fax 41 21 345 91 20
Shares Short Prior Month 796919 Return On Equity -0.3116 City Lausanne
Uuid 85843cf1-545c-39be-aeb0-e49af7d9f82e Previous Close 3.40 First Trade Date Epoch Utc 1 B
Book Value 1.30 Beta 1.28 Total Debt 3 M
Volume 61270 Price To Book 2.58 Fifty Two Week Low 2.25
Total Cash Per Share 1.58 Total Revenue 40 M Shares Short Previous Month Date 1 B
Target Median Price 7.54 Max Age 86400 Recommendation Mean 1.25
Sand P52 Week Change 0.3133 Operating Margins 28.52 % Target Mean Price 9.02
Net Income To Common -39863000 Short Percent Of Float 0.0199 Implied Shares Outstanding 99 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 163190
Average Volume10days 163190 Total Cash 157 M Next Fiscal Year End 1 B
Revenue Per Share 0.4250 Held Percent Insiders 0.2183 Ebitda Margins -87.27 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 3.40 Target Low Price 6.79 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.30 Open 3.43 Free Cashflow 49 M
Dividend Yield 0.00 % Return On Assets -0.1204 Time Zone Short Name EST
Trailing Eps -0.4500 Day Low 3.35 Address1 Building B
Shares Outstanding 98 M Price Hint 4 Target High Price 14.19
Website https://www.acimmune.com 52 Week Change 0.0151 Average Volume 102451
Forward Eps -0.2500 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 182.30 % Is_sp_500 False Regular Market Day High 3.43
Profit Margins -97.29 % Debt To Equity 2.37 Fifty Two Week High 5.14
Day High 3.43 Shares Short 1 M Regular Market Open 3.43
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 4.41
Revenue Growth 0.00 % Shares Percent Shares Out 0.0107 Operating Cashflow 43 M
Currency USD Time Zone Full Name America/New_York Market Cap 332 M
Is_nasdaq_100 False Zip 1015 Quote Type EQUITY
Industry Biotechnology Long Name AC Immune SA Regular Market Day Low 3.35
Held Percent Institutions 0.2881 Current Price 3.36 Address2 EPFL Innovation Park
Enterprise To Ebitda -5.05 Financial Currency CHF Current Ratio 1.86
Gross Margins -49.93 % Industry Disp Biotechnology Number Of Analyst Opinions 4
Country Switzerland Float Shares 40 M Two Hundred Day Average 3.36
Enterprise Value 180 M Price To Sales Trailing12 Months 8.11 Forward PE -110.78
Regular Market Volume 61270 Ebitda -35758000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.

The company is also developing ACI-24.

060 for the treatment of down syndrome-related AD; ACI-7104.

056, to treat Parkinson's disease; and ACI-35.

030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau.

In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease.

Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies.

Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3.

The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company.

AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.